Yavuz Sule, Lipsky Peter E
Department of Medical Sciences, Rheumatology, Uppsala University, Uppsala, Sweden.
Ampel BioSolutions and Re-Imagine Lupus Investigation, Treatment and Education Research Institute, Charlottesville, VA, United States.
Front Med (Lausanne). 2021 May 28;8:682544. doi: 10.3389/fmed.2021.682544. eCollection 2021.
The vastly diverse nature of systemic lupus erythematosus (SLE) poses great challenges to clinicians and patients, as well as to research and drug development efforts. Precise management of lupus patients would be advanced by the ability to identify specific abnormalities operative in individual patients at the time of encounter with the clinician. Advances in new technologies and bioinformatics have greatly improved the understanding of the pathophysiology of SLE. Recent research has focused on the discovery and classification of sensitive and specific markers that could aid early accurate diagnosis, better monitoring of disease and identification of appropriate therapy choices based on specific dysregulated molecular pathways. Here, we summarize some of the advances and discuss the challenges in moving toward precise patient-centric management modalities in SLE.
系统性红斑狼疮(SLE)的多样性给临床医生、患者以及研究和药物开发工作带来了巨大挑战。能够识别个体患者在就诊时存在的特定异常情况,将有助于推进对狼疮患者的精准管理。新技术和生物信息学的进展极大地增进了我们对SLE病理生理学的理解。近期的研究聚焦于发现和分类敏感且特异的标志物,这些标志物有助于早期准确诊断、更好地监测疾病,并基于特定失调的分子途径确定合适的治疗选择。在此,我们总结了一些进展,并讨论了在迈向以患者为中心的SLE精准管理模式过程中所面临的挑战。